Plus Therapeutics

15 Million Financing And Oncology Trials Will Secure Clinical Progress

AnalystConsensusTarget

Not Invested

Consensus Narrative from 3 Analysts

Published

20 Apr 25

Updated

15 Aug 25

AnalystConsensusTarget's Fair Value

US$9.17

94.3% undervalued

15 Aug

US$0.52

-66.3%

-28.4%

Author's Valuation

US$9.2

94.3% undervalued

AnalystConsensusTarget Fair Value

Narrative

Updates2

Shared on01 May 25

Shared on24 Apr 25
Fair value Decreased 8.33%

AnalystConsensusTarget Fair Value

US$9.2

94.3% undervalued

Future estimation in

% p.a.

Decrease

Increase

Current revenue growth rate

65.12%

Biotech revenue growth rate

12.78%

Risk Level (Discount Rate)

Our default considers factors like the company's size, volatility, profitablity and country of operation.

Decrease

Increase

Current discount rate

6.78%

Calculation

US$2.86m

Earnings '28

145.63x

PE Ratio '28

US$416.77m

Market Cap '28

US$416.77m

Market Cap '28

37.35m

No. shares '28

US$11.16

Share Price '28

US$11.16 Share Price '28

Discounted to 2025 @ 6.78% p.a.

US$9.17

Fair Value '25

15 Million Financing And Oncology Trials Will Secure Clinical Progress

Shared on01 May 25

Shared on24 Apr 25Fair value Decreased 8.33%

Shared on24 Apr 25
Fair value Decreased 8.33%